Our previous study demonstrated that sildenafil may directly improve the sexuality of women affected by arousal disorders and thus other sexual qualitative functions such as enjoyment and orgasm [15]; sildenafil may play an indirect therapeutic role in the quantitative aspects of sexual function, such as the frequency of sexual fantasies and the frequency of sexual intercourse. We showed that sildenafil was efficacious and safe on women with symptomatic sexual arousal dysfunction (placebo-controlled study). However, we thought that further studies would be needed to verify the efficacy and safety of this PDE5 inhibitor, studying healthy women asymptomatic for sexual dysfunctions, by examining the activity and the influence of the drug on female sexuality.
6. Response and effectiveness
Currently, there are potential therapeutic options for the treatment of FSD and these options include both hormonal and pharmacological therapies [11]. However, sex therapists are discovering that integrating adjunctive use of drugs with sex therapy can accelerate the therapy process and improve outcome. As new pharmaceuticals are developed and approved for both men and women, opportunities for medical and non-medical sex therapies will only increase [12]. Sildenafil, a selective phosphodiesterase type 5 (PDE5) inhibitor, taken orally, promotes penile erection through an increase in intracellular cGMP levels, in response to sexual stimulation, thus increasing smooth muscle relaxation [13]. Moreover, it has been shown to be able to inhibit PDE5 that is present in intact cells and soluble extracts of human clitoral corpus cavernosum smooth muscle cells [14]. Check access to the full text by signing in through your organization.
- The use of sildenafil in women is still under scientific investigation.
- Some women report benefits, but evidence is not definitive.
- Potential risks must be carefully weighed against benefits.
- Proper medical guidance is essential for safe use.
The study protocol was approved by the Institutional Review Board of the Department and conformed to the ethical guidelines of the 1975 Helsinki Declaration. The study was performed at the Family Planning Centre of the Group for Sexological Research of the Department of Microbiological and Gynecological Science, School of Medicine, University of Catania, Italy.
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Headache | Mild to Moderate | Common | Analgesics, hydration |
| Flushing | Mild | Common | Cooling measures |
| Dizziness | Mild | Occasional | Sit/lie down, avoid sudden standing |
| Nasal Congestion | Mild | Common | Decongestants if needed |
| Vision Changes | Rare | Rare | Stop medication if occurs |
Based on results of differences between baseline and sildenafil oral jelly 100mg sildenafil 50 mg of 2.7 in female arousal dysfunction score [15], with α=0.05 and 1− Of the 68 women enrolled in the study, 50 aged 19–38 years, with a mean age (S.D.) of 27 (2.1) years, provided information at each treatment, and at the first follow-up to be included in the analyses (Fig.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 100mg | 120 + 6 Pills | 149.50€ 142.38€ | |
| Kamagra Soft Tabs | 100mg | 180 + 8 Pills | 425.45€ 405.19€ | |
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Kamagra Oral Jelly | 100mg | 110 + 9 Sachets | 334.87€ 318.92€ | |
| Kamagra Soft Tabs | 100mg | 60 + 4 Pills | 180.59€ 171.99€ | |
| Kamagra Soft Tabs | 100mg | 12 Pills | 57.55€ 54.81€ | |
| Viagra Generic | 25mg | 360 + 10 Pills | 213.68€ 203.50€ | |
| Viagra Generic | 150mg | 20 Pills | 55.02€ 52.40€ | |
| Viagra Generic | 150mg | 10 Pills | 36.73€ 34.98€ | |
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Kamagra Polo | 100mg | 120 + 6 Pills | 327.15€ 311.57€ |
Eighteen women were excluded after assessment at baseline: (i) four for bisexual relationships, (ii) 10 for more than one sexual partner, and (iii) four for refused treatment. Moreover, 12/50 women did not undergo the second follow-up: two of them had changed their partners, both during After extensive bibliographic and database research (years 1999–2002, key words: sildenafil; efficacy; safety; FSD; asymptomatic pre-menopausal women for FSD), we can state that this is the first clinical research conducted on pre-menopausal women, asymptomatic for sexual dysfunction, to study the efficacy and the safety of sildenafil. The two-period cross-over study design allowed us to obtain outcomes from each individual woman during the use of sildenafil with respect to placebo assumption.
Other approaches
The main reason for this was the successful introduction of oral pharmacotherapy for the treatment of male erectile dysfunction [2]. Risk factors for FSD are probably both psychological and physiological [3]. This raised the question of whether a vascular medication such as sildenafil would be efficacious for FSD [4]. However, one of the most important impediments to the research and the clinical development has been the lack of definite diagnostic procedures and a widely accepted classification of FSDs [5]. It has become increasingly evident that FSD can occur secondary to medical problems and have an organic basis.
Eur. Urol.
On the other hand, anatomical aspects such as the biological mechanism of sexual excitement and of orgasm have not been well defined [6]. The female genital sexual response cycle is mediated via the release of neurotransmitters causing relaxation of vascular and non-vascular smooth tissue, increased pelvic blood flow, vaginal lubrication, and clitoral and labial engorgement, involving the nitric oxide-cGMP pathway [7], [8]. Moreover, the drugs acting on vessels, largely used in the treatment of erectile dysfunctions, may certainly play a role in any female counterpart of problematic genital engorgement. Attention has to be given to the buy sildenafil uk physiological and pathophysiological evaluation of clitoral function [9]. The clitoris, characterized by large innervations and vascularization, could be considered as an equivalent to the penis, being endowed with a considerable sensitivity [10]. Female sexual response: the role of drugs in the management of sexual dysfunctionObstet. et al.Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled studyBr. et al.Sexual dysfunction in the United States: prevalence and predictorsJAMA(1999) Prevalence of and recent developments in female sexual dysfunctionCurr.
How Does Viagra Affect Women?
It should not be used more than once a day or more than eight times a month. Side effects can include nausea, headache, vomiting and reactions at the site of the shot. Talk with your healthcare professional to see if this medicine might be right for you. Sexual problems may be due to trouble with arousal, a lack of desire or both. Many factors can affect sexual desire in women.
Cite this article
Many women find that the stresses of daily life lower their desire for sex. Highs and lows in sexual desire may go along with the beginning or end of a relationship or with major life changes, such as pregnancy or menopause. For some women, orgasm can be hard to reach. This can cause worries that lead to a loss of interest in sex. Desire often is linked to a sense of closeness between partners, as well as sexual issues from the past.
Comparison table
Some chronic conditions, such as diabetes or multiple sclerosis, can cause changes in arousal or orgasm. If you have trouble with sexual desire or response, talk with a member of your healthcare team. You might want to talk to a sex therapist. Medicines, hormones, creams, sildenafil citrate tablets 50 mg lubricants, clitoral stimulation or other treatments sometimes can help. There is a problem with information submitted for this request. Definition and classification of female sexual disordersInt. et al.Anatomy and physiology of female sexual function and dysfunction: classificationEur. Female Sexual Dysfunction—Medical and Psychological Treatments, Committee 142017, Journal of Sexual Medicine Biochemical Factors Modulating Female Genital Sexual Arousal Physiology2010, Journal of Sexual Medicine Physiology of female sexual function: Animal models2004, Journal of Sexual Medicine Polymer-based nitric oxide therapies: Recent insights for biomedical applications2012, Advanced Functional Materials Women's orgasm2004, Annual Review of Sex Research To evaluate the efficacy, safety and tolerability of oral sildenafil in women with female sexual arousal disorder as a result of SCI (paraplegia/tetraplegia). The study was conducted at clinical practice sites in North America (n =23), 11 European countries (n =23), Australia (n =4) and South Africa (n =2). 129 women were randomized and treated with sildenafil or matching placebo. A 4-week baseline period was followed by 12 weeks of treatment, which could be increased from 50 to 100 mg or decreased to 25 mg once during the treatment period, depending on efficacy and tolerability.
- Discussions with healthcare providers are crucial before considering sildenafil.
- Female sexual dysfunction may have hormonal, psychological, or physical causes.
- Sildenafil should never be used with other medications without medical approval.
- Its use in women should be part of a broader treatment plan.
By use of an event log, sexual activity was monitored between screening and the end of treatment. The Sexual Function Questionnaire, the Sexual Quality of Life Questionnaire–Female, a global efficacy question and Sexual Distress Question were also assessed.
5. Tips
Review/update the information highlighted below and resubmit the form. Women’s health topics - straight to your inbox Get the latest information from our Mayo Clinic experts on women’s health topics, serious and complex conditions, wellness and more. Click to view a preview and subscribe below. Learn more about Mayo Clinic’s use of data. We use the data you provide to deliver you the content you requested.
Osphenia (Ospemifene)
To provide you with the most relevant and helpful information, we may combine your email and website data with other information we have about you. If you are a Mayo Clinic patient, we will only use your protected health information as outlined in our Notice of Privacy Practices. You may opt out of email communications at any time by clicking on the unsubscribe link in the email. You'll soon start receiving the latest Mayo Clinic health information you requested in your inbox. American Association for Marriage and Family Therapy.
Br. J. Obstet. Gynaecol.
Overview of sexual dysfunction in women: Management. Volume 110, Issue 2, 10 October 2003, Pages 201-206 Female sexual dysfunction (FSD) is a new, rapidly expanding area of sexual medicine. Female sexual disorders are diffused and can provoke severe repercussions on mood, self-esteem and personal relations. According to the National Health and Social Life Survey, one-third of women show loss of sexual interest, while a quarter of them show absence of orgasm experience [1]. In the past few years, sexual disorders have attracted much attention, generating new research in the epidemiology, pathophysiology and pharmacotherapy of FSD. Sildenafil-treated women and placebo-treated women had an increase in their percentage of sexual activities throughout the course of the study, with no statistically significant difference between groups in the percentage of successful sexual activities at end of treatment versus baseline. There were also no statistically significant differences between sildenafil- and placebo-treated women on the aforementioned measures. The most common adverse events included headache and vasodilatation.
- Sildenafil is being studied for female sexual dysfunction.
- It may improve blood flow to vaginal tissues.
- Not officially approved for women in many countries.
- Side effects can include headaches and flushing.
The results of this study are similar to other reports regarding a lack of clinically meaningful benefit of sildenafil in other populations of women.